March 13-14, 2020

The Roosevelt Hotel
45 East 45th Street & Madison Avenue
New York, New York 10017

Physicians’ Education Resource^®, LLC, understands the concerns surrounding the outbreak and spread of the coronavirus (COVID-19) currently affecting several countries. After monitoring the situation and information being shared by the CDC, and taking into account current travel restrictions, we have decided that the New York GU 13th Annual Interdisciplinary Prostate Cancer Congress^®, and Other Genitourinary Malignancies will go on as scheduled. Be assured that there is nothing more important to us than the safety of our participants; therefore, we have worked with our host hotel and taken steps to implement additional precautions on-site to keep our attendees safe at this year’s conference. We look forward to seeing you there.

New York GU 13th Annual Interdisciplinary Prostate Cancer Congress^® and Other Genitourinary Malignancies will provide a comprehensive overview of genitourinary malignancies with a focus on urothelial, prostate, and renal cancers. Faculty will present brief and insightful presentations covering a range of topics that will include diagnostic molecular pathology, current and evolving therapeutic strategies, and best practices for managing advanced disease. You will have the opportunity to hear the expert faculty as they engage in challenging case debates and gain insight into some of the most challenging issues facing your clinical practice. You will leave with the confidence to maintain current standards of care and implement the best new strategies into your clinical practice.

You won’t want to miss this conference! Now in its 13th year, the 2020 New York GU™ meeting offers you the opportunity to advance your understanding and knowledge of state-of-the-art care for patients with genitourinary malignancies.

This activity is supported by educational grants from Astellas; AstraZeneca; Exelixis, Inc.; Genomic Health, Inc.; Merck & Co., Inc.; Pfizer Inc.; Sanofi Genzyme; and Seattle Genetics, Inc.

Physicians' Education Resource^®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC, designates this live activity for a maximum of 13.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource^®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 13.5 Contact Hours.

This educational activity is directed toward medical, surgical, and radiation oncologists involved in the treatment of patients with GU malignancies. Urologists, fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, nuclear medicine physicians, and other healthcare professionals interested in the treatment of GU malignancies may also participate.

After this activity, participants should be better prepared to:

1. Outline the molecular pathology of GU tumors and current and emerging diagnostic concepts in GU cancers
2. Describe current approaches and practice-changing clinical evidence for the management of patients with GU malignancies across multiple lines of care
3. Explain strategies for monitoring, recognizing, and mitigating treatment-related toxicities associated with therapies used for GU cancers
4. Determine how recent landmark findings from trials conducted among patients with GU malignancies can be placed in the context of evolving treatment paradigms in urology and medical oncology practices

• Applying molecular markers toward decision making for GU cancers
• Updates in clinical immunotherapy across tumor types
• Best practices for advanced bladder cancer (BC), renal cell carcinoma (RCC), and prostate cancer (PC)
• Emerging therapies in GU cancers
• The latest progress in next-generation imaging for PC
• New concepts for screening in PC
• Updates in PARP Inhibitors for PC
• Practical guidance on managing early BC
• Monotherapy versus combination therapy update in RCC
• Challenging case debates
• And more!